LBA
PVLA

Letko, Brosseau & Associates’s Palvella Therapeutics PVLA Stock Holding History

Letko, Brosseau & Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$436K Hold
3,500
– – 0.01% 80
2025
Q4 		$366K Sell
3,500
-1,700
-33% -$145K 0.01% 82
2025
Q3 		$326K Buy
+5,200
New +$232K 0.01% 83

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Letko, Brosseau & Associates's PVLA Position: Q1 2026 in Review

Letko, Brosseau & Associates held its Palvella Therapeutics (PVLA) position steady in Q1 2026 at 3,500 shares worth $436K. The position accounts for 0.01% of the portfolio, ranked #80.

Letko, Brosseau & Associates first reported a position in PVLA in Q3 2025 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Letko, Brosseau & Associates held 3,500 shares of Palvella Therapeutics worth $436K as of Q1 2026.
  • Letko, Brosseau & Associates left its Palvella Therapeutics share count unchanged in Q1 2026.
  • Palvella Therapeutics made up 0.01% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #80 holding.
  • Letko, Brosseau & Associates first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.